GlassScriptPhysician profile
Lawrence F Berg
NPI 1205940160
$5,093.23
in general payments reported to CMS, 2019-2025
13 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $104 · 2022: $2,044 · 2023: $2,131 · 2024: $377 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,513 · Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,513.37 |
| Food and Beverage | $1,135.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,039.17 | 2020-2025 | Scopis Ent |
| Medtronic, INC. | $2,037.10 | 2023-2024 | Propel, Sinuva |
| Intersect Ent, INC. | $265.02 | 2019 | |
| Neurent Medical Limited | $208.22 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Genzyme Corporation | $143.31 | 2024-2025 | |
| Aerin Medical INC. | $94.30 | 2019-2024 | |
| Watermark Medical, INC. | $75.94 | 2022 | |
| Glaxosmithkline, LLC. | $75.58 | 2024-2025 | Nucala |
| Optinose US, INC. | $40.75 | 2019-2022 | |
| Smith+Nephew, INC. | $38.76 | 2023 | Tula, Halo, Ent Sinus |
| Acclarent, INC | $36.56 | 2022-2023 | Relieva Spinplus, Acclarent Aera |
| Regeneron Healthcare Solutions, INC. | $23.20 | 2023 | Dupixent |
| Csl Behring | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.